相关实验视频

Updated: Jul 19, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

在小儿 β-thalassemia major 中系统识别和验证由 ceRNA 驱动的调节机制

Tao Wu^1,2, Zhenmin Ren¹, Xiaorong Liu¹

¹Department of Laboratory Medicine, Shenzhen Children's Hospital, Futian District, 7019 Yitian Road, Shenzhen, 518038, NoGuangdong, China.

Annals of hematology

|February 10, 2025

概括

研究人员发现了一种新途径,涉及循环RNA,微RNA和GATA2,可以促进胎儿血红蛋白 (HbF) 产生. 这一发现为β-thalassemia major (β-TM) 提供了潜在的新疗法.

科学领域:

分子生物学分子生物学
遗传学遗传学是一个
血液学血液学血液学

背景情况:

胎儿血红蛋白 (Hb F) 反激活是治疗β-血红蛋白病的治疗策略.
微RNAs (miRNAs) 调节基因表达,而竞争的内源RNAs (ceRNAs) 可以影响miRNA活动.
在β-thalassemia major (β-TM) 中ceRNAs的作用及其对γ-globin表达的影响尚不清楚.

研究的目的:

为了研究ceRNAs在β-thalassemia major (β-TM) 中的作用.
确定影响β-TM中的γ-环球蛋白表达的特定ceRNA通路.
探索基于ceRNA网络的β-TM的潜在治疗点.

主要方法:

从β-TM患者和健康对照组中进行转录组测序 (circRNA,miRNA,mRNA).
生物信息学分析构建一个GATA2相关的ceRNA网络.
使用qRT-PCR,RNA免疫沉和双露西法酶记者分析进行验证.

主要成果:

一个新的ceRNA路径hsa_circ_0005245‐hsa‐miR‐425‐3p‐GATA2被确定并验证.
在HUDEP-2细胞中,hsa_circ_0005245,hsa-miR-425-3p或GATA2的过度表达单独增加了γ-环球蛋白水平.
证实了这种途径可以调节γ-环球蛋白表达.

结论:

这项研究确定了一种新型的ceRNA途径,该途径调节β-TM中的γ-环球蛋白表达.
这一途径,hsa_circ_0005245‐hsa‐miR‐425‐3p‐GATA2,为β-TM提供了一个潜在的治疗点.
这些发现为β-TM患者的临床管理提供了新的见解.

关键词:

在 GATA2 中.这就是CeRNA.大型β - thalassemia 的情况.γ-环球蛋白是一种

更多相关视频

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...